Reuters logo
BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity
2017年10月17日 / 凌晨12点27分 / 1 个月前

BRIEF-Astrazeneca says co and Chi-med's Savolitinib shows encouraging clinical activity

Oct 16 (Reuters) - Astrazeneca Plc

* Astrazeneca and Chi-med’s Savolitinib shows encouraging clinical activity in 2nd-line EGFR mutation-positive lung cancer with met-amplification

* Data give insights into disease progression,potential next-generation treatment strategies in patients with EGFR-mutated NSCLC with met-amplification​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below